GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress
Retrieved on:
Tuesday, September 6, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, PAKT, Research, Professor, Rosacea, KA, Science, Frontiers of Medicine, Congress, AM, Population, IL-31, Thought, Patient, Genetics, RESEARCH, Atopic dermatitis, Sensitive, Woman, Prurigo nodularis, Adapalene, Partnership, Chairperson, Skin, Investment, Acne, Acquisition, Prurigo, Benzoyl peroxide, European Academy of Management, Nervous system, Cetaphil, Onychomycosis, Diagnosis, PM, Perkinsus marinus, Nail, Pharmaceutical industry, Cosmetics, Sculptra, Trifarotene, Methyl aminolevulinate, Ivermectin, Adapalene/benzoyl peroxide, Venereology, Galderma, Dermatology
Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022.
Key Points:
- Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022.
- As the pure-play dermatology leader, Galdermas significant presence at EADV reaffirms its commitment to delivering a truly innovative, science-based portfolio of premium cutting-edge brands and services.
- Two symposia and eight scientific posters will examine the disease burden, the role of IL-31 in these inflammatory skin conditions and treatments under development.
- EADV congress to exchange information, share insights and
GLOBAL HEAD OF RESEARCH & DEVELOPMENT, GALDERMA
Below is a full list of activities taking place.